95522-45-5

95522-45-5 structure

Name: Colestilan
Chemical Name: 2-(chloromethyl)oxirane,2-methyl-1H-imidazole
CAS Number: 95522-45-5
Molecular Formula: C₇H₁₁ClN₂O
Molecular Weight: 174.62800
Catalog: Research Areas Metabolic Disease
Create Date: 2018-06-16 00:36:38
Modify Date: 2024-01-09 20:25:18
Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].

Name	2-(chloromethyl)oxirane,2-methyl-1H-imidazole
Synonyms	Colestilan Epichlorohydrin-2-methylimidazole copolymer Colestimide MCI 196 Cholebine

Description	Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract[2]. Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro[2].
In Vivo	Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats[3]. Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks[1]. Animal Model: 6-week old Wistar male rats[3] Dosage: 0.125 or 0.5 g content per 15 g of the feed Administration: Oral in feed, 14 days Result: Dose dependently decreased blood phosphate and urinary phosphate excretion.
References	[1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81. [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30. [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.

Molecular Formula	C₇H₁₁ClN₂O
Molecular Weight	174.62800
Exact Mass	174.05600
PSA	41.21000
LogP	1.34210

2138254-92-7	1158522-08-7
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	2227803-03-2